Replies to post #108813 on Regen BioPharma Inc (RGBP)

[Musical Shares]

RGBP looking like its getting close!

Close to what? There is nothing RGBP is getting close too. They aren't researching anything. So how does a biotech company "get close" to something?

Dr Koos will be working on funding and advertising of IP.

No he isn't. Where did this information come from? Funding from where? He just defaulted on a toxic loan. Advertising of what? He has no products.

What absolute nonsense.

And with the science finally catching up with NR2F6, and gene suppression, it truly is just a sit, wait, and watch Dr Koos position this companies IP for marketability.

There is no science "catching up" with NR2F6 to the extent of ANYTHING coming close to marketing a product.

NR2F6 is still missing a confirmed selective ligand.

Little is known about the molecular workings of NR2F6 and it's function on said molecular level.

Koos is working so hard

Working hard at what? The past year he didn't develop any new patents or research. Getting current and paying patent fees for prior science isn't "working hard."

Again, in the OTC, "working hard" is about paying past dues and getting caught up with paperwork.

and is now in provably better position then ever to capitalize on its NR2F6 science.

It's not any closer to developing marketable drugs.

The closest step that has been achieved with NR2F6 is doing a larger scale HST study. This was done by Emery Smith, Sean Campbell, Adrianna Wilson and a handful of others from The Scripps Research Institute.

There is still no bona fide ligand.